Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 76% of modeled bridge. Strengths: Occupancy Rate, Revenue per Bed. Risks: Commercial Payer %. Risk-adjusted uplift: $6.1M (vs $8.0M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $3.0M | $3.0M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $2.9M | $83K | $3.0M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $465K | $1.4M | $1.8M | $5.8M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $97K | $97K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 58.7% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $758K | $1.5M | $2.3M | $3.0M | $3.0M | $3.0M | $3.0M |
| Denial Rate Reduction | $0 | $750K | $1.5M | $2.3M | $3.0M | $3.0M | $3.0M | $3.0M |
| A/R Days Reduction | $0 | $615K | $1.2M | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M |
| Clean Claim Rate | $0 | $48K | $97K | $97K | $97K | $97K | $97K | $97K |
| Cumulative | $0 | $2.2M | $4.3M | $6.5M | $8.0M | $8.0M | $8.0M | $8.0M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $8.0M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 55% / 9.1x | 60% / 10.5x | 64% / 11.8x | 66% / 12.5x | 68% / 13.2x |
| 9.0x | 50% / 7.7x | 55% / 8.9x | 59% / 10.2x | 61% / 10.8x | 63% / 11.4x |
| 10.0x | 46% / 6.6x | 50% / 7.7x | 55% / 8.8x | 56% / 9.4x | 58% / 9.9x |
| 11.0x | 42% / 5.7x | 46% / 6.7x | 50% / 7.7x | 52% / 8.2x | 54% / 8.7x |
| 12.0x | 38% / 5.0x | 43% / 5.9x | 47% / 6.8x | 49% / 7.3x | 50% / 7.7x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 15% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 5.5x, adding 2.9 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $15.1M | — | $15.1M | 10.0% |
| Year 1 | $15.6M | +$5.3M | $20.9M | 13.8% |
| Year 2 | $16.0M | +$8.0M | $24.0M | 15.8% |
| Year 3 | $16.5M | +$8.0M | $24.5M | 16.2% |
| Year 4 | $17.0M | +$8.0M | $25.0M | 16.5% |
| Year 5 | $17.5M | +$8.0M | $25.5M | 16.8% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $1.5M | $2.3M | $3.0M | $3.6M |
| Denial Rate Reductio | $1.5M | $2.3M | $3.0M | $3.6M |
| A/R Days Reduction | $922K | $1.4M | $1.8M | $2.2M |
| Clean Claim Rate | $48K | $73K | $97K | $116K |
| Total | $4.0M | $6.0M | $8.0M | $9.6M |
Peer Context — Where This Hospital Sits
Key metrics vs 29 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 10.0% | -16.1% | -6.1% | 3.7% | P86 |
| Net-to-Gross | 47.9% | 41.8% | 49.6% | 58.7% | P45 |
| Occupancy | 77.3% | 39.3% | 50.8% | 62.8% | P86 |
| Rev/Bed | $3.8M | $2.0M | $2.8M | $4.3M | P66 |
| Exp/Bed | $3.4M | $1.8M | $3.4M | $4.7M | P52 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.